title: Functional promoter -31G>C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population.
abstract: BACKGROUND
  Survivin is an inhibitor of apoptosis protein and is involved in the occurrence and progression of human malignancies. Recently, a functional polymorphism (-31G>C, rs9904341) in the promoter of survivin has been shown to influence its expression and confer susceptibility to different types of cancer. The present study was aimed to investigate whether the polymorphism also influences susceptibility and progression of renal cell cancer (RCC) in a Chinese population.
  
  
  METHODS
  We genotyped this polymorphism using the TaqMan assay in a case-control study comprised of 710 RCC patients and 760 controls. The logistic regression was used to assess the genetic association with occurrence and progression of RCC.
  
  
  RESULTS
  Compared with the genotypes containing G allele (GG and GC), we found a statistically significant increased occurrence of RCC associated with the CC genotype [P = 0.006, adjusted odds ratio (OR) = 1.38, 95% confidence interval (CI) = 1.08-1.76]. The polymorphism was associated with risk of developing advanced stage (OR = 2.02, 95%CI = 1.34-3.07) and moderately differentiated (OR = 1.75; 95%CI = 1.20-2.54) RCC. Furthermore, the patients carrying the CC genotype had a significantly greater prevalence of high clinical stage disease (P(trend) = 0.003). Similar results were also observed when we restricted the analysis to clear cell RCC, a major histological type of RCC.
  
  
  CONCLUSIONS
  Our results suggest that the functional -31G>C polymorphism in the promoter of survivin may influence the susceptibility and progression of RCC in the Chinese population. Large population-based prospective studies are required to validate our findings.
authors.affiliation: Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
authors.forename: Chao
authors.initials: C
authors.lastname: Qin
authors.forename: Qiang
authors.initials: Q
authors.lastname: Cao
authors.forename: Pu
authors.initials: P
authors.lastname: Li
authors.forename: Xiaobing
authors.initials: X
authors.lastname: Ju
authors.forename: Meilin
authors.initials: M
authors.lastname: Wang
authors.forename: Jiawei
authors.initials: J
authors.lastname: Chen
authors.forename: Yilong
authors.initials: Y
authors.lastname: Wu
authors.forename: Xiaoxin
authors.initials: X
authors.lastname: Meng
authors.forename: Jian
authors.initials: J
authors.lastname: Zhu
authors.forename: Zhengdong
authors.initials: Z
authors.lastname: Zhang
authors.forename: Qiang
authors.initials: Q
authors.lastname: Lu
authors.forename: Changjun
authors.initials: C
authors.lastname: Yin
mesh_terms: D044466:Asian People / Q000235:genetics*; D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D018450:Disease Progression; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics*; D007680:Kidney Neoplasms / Q000235:genetics / Q000473:pathology; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011401:Promoter Regions, Genetic / Q000235:genetics*; D000077022:Survivin
chemical_list: C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin